Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

BACKGROUND: Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for early-stage breast cancer. Doxorubicin is a substrate for ABCB1 and SLC22A16 transporters. Cyclophosphamide is a prodrug that requires oxidation to 4-hydroxycyclophosphamide, which yields a cytotoxic alkylating a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bray, J, Sludden, J, Griffin, M J, Cole, M, Verrill, M, Jamieson, D, Boddy, A V
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844036/
https://www.ncbi.nlm.nih.gov/pubmed/20179710
http://dx.doi.org/10.1038/sj.bjc.6605587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844036/
https://www.ncbi.nlm.nih.gov/pubmed/20179710
http://dx.doi.org/10.1038/sj.bjc.6605587

Ejemplares similares